Lantheus

Lantheus Holdings, Inc. is a prominent radiopharmaceutical company based in Billerica, Massachusetts, founded in 1956. The company specializes in developing, manufacturing, and commercializing diagnostic and therapeutic products that assist clinicians in detecting, treating, and monitoring diseases, with a focus on oncology and cardiology. Lantheus's core offerings include a variety of radiopharmaceuticals, such as diagnostic imaging agents and radiotherapeutics. Notable products in its portfolio are DEFINITY®, an ultrasound contrast agent, and advanced PET imaging agents for Alzheimer’s disease and oncology. The company has expanded its capabilities through strategic acquisitions, enhancing its portfolio in radiopharmaceutical oncology and neurodegenerative disease imaging. Lantheus serves a diverse range of customers, including healthcare providers, hospitals, and imaging centers, and maintains partnerships with major healthcare and pharmaceutical companies. The company went public on NASDAQ in 2015 and has shown strong financial performance, with reported worldwide revenue of $1.53 billion in 2024. Lantheus is committed to advancing radiodiagnostic and radiotherapeutic solutions to improve patient outcomes globally.